- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07714291
CPHARM - CRC Study
Community Pharmacy-Based Health-Seeking Behaviour and Colorectal Cancer Screening Uptake Among Malaysian Adults
Colorectal cancer is one of the most common cancers in Malaysia and worldwide. Although it can often be prevented or treated successfully when detected early, many people in Malaysia are diagnosed at an advanced stage. Screening tests, such as the immunochemical faecal occult blood test (iFOBT), can help detect early signs of colorectal cancer; however, participation in screening remains low.
Community pharmacies are easily accessible healthcare settings where people frequently seek health advice. Pharmacists may play an important role in improving awareness and encouraging colorectal cancer screening by providing education and support. However, more information is needed to understand how people perceive and respond to pharmacy-based colorectal cancer screening.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Yen Jun Wong
- Telefonnummer: 60355146286
- E-post: yenjun.wong@monash.edu
Studera Kontakt Backup
- Namn: Chee Tao Chang
- E-post: davidcct.crc@gmail.com
Studieorter
-
-
Selangor
-
Klang, Selangor, Malaysia, 41050
- Big Caring Group
-
Kontakt:
- Shiau Hueh Yeow
- Telefonnummer: 60374531988
- E-post: shiauhueh.yeow@bigcaring.com.my
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Adults aged 50 to 75 years
- Visiting participating community pharmacies during the study period
- Able to provide informed consent
- Willing to complete the study questionnaire
- Willing to provide consent for follow-up assessment of: iFOBT provision, iFOBT testing completion, iFOBT results
Exclusion Criteria:
- Previous diagnosis of colorectal cancer
- History of colonoscopy within the recommended screening interval (within past 1 year)
- Currently experiencing symptoms suggestive of colorectal cancer
- Having a first-degree relative diagnosed with colorectal cancer
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Pharmacy customers with campaign
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
|
Inget ingripande: Pharmacy customers without campaign
Customers will receive standard pharmacy services such as medication dispensing and general health advice, but no educational materials or one-on-one education on CRC will be provided.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening
Tidsram: From enrollment to the 8th week follow-up.
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening, measured using the Champion Health Belief Model Scale - Colorectal Cancer - Malay (CHBMS-CRC-M) subscales of perceived susceptibility, perceived benefits, and perceived barriers, between customers from pharmacies with and without the one-day awareness campaign. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Domain scores will be calculated by summing (or averaging) the items within each domain, with higher scores indicating greater perceived susceptibility, benefits or barriers. |
From enrollment to the 8th week follow-up.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Proportion of participants who were willing to accept and perform iFOBT, report iFOBT results, and follow-up if needed.
Tidsram: From enrollment to the 8th week of follow-up
|
From enrollment to the 8th week of follow-up
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 53176
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .